The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1470
June 8, 2015
View Complete Issue         Table of Contents 2019 
Nivolumab (Opdivo) for Metastatic Melanoma and Metastatic NSCLC
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Nivolumab (Opdivo) for Metastatic Melanoma and Metastatic NSCLC
June 8, 2015 (Issue: 1470)
The FDA has approved nivolumab (Opdivo – BMS), an IV programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic melanoma that has progressed following treatment with ipilimumab (and a BRAF inhibitor in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Nivolumab (Opdivo) for Metastatic Melanoma and Metastatic NSCLC
Article code: 1470b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.